BRIEF-Novavax Says Topline Efficacy Data From Prepare Phase 3 Clinical Trial Expected In Q1 Of 2019 By: Reuters: Company News May 07, 2018 at 07:14 AM EDT * NOVAVAX REACHES SIGNIFICANT ENROLLMENT MILESTONE IN THE PREPARE(TM) PHASE 3 TRIAL OF ITS RSV F VACCINE Read More >> Related Stocks: Novavax Inc